Teens with advanced-stage Hodgkin lymphoma survive longer without their disease getting worse when they receive the ...

Reversing the standard approved dose levels of nivolumab (Opdivo) and ipilimumab (Yervoy) in metastatic melanoma led to less ...

The FDA approved nivolumab and ipilimumab for unresectable or metastatic hepatocellular carcinoma, a prevalent and deadly liver cancer in the U.S. CHECKMATE-9DW trial results showed improved median ...

A Prescription Drug User Fee Act target date of June 23, 2025 has been set for the application. The sBLA is supported by data from the randomized, open-label phase 3 CheckMate 8HW trial ...

SAN FRANCISCO -- An immunotherapy combination for advanced, highly mutated colorectal cancer (CRC) significantly slowed disease progression versus a single drug, according to a randomized study.

Please provide your email address to receive an email when new articles are posted on . The 7-year intracranial progression free-survival among patients treated with combination therapy was 42%.

Please provide your email address to receive an email when new articles are posted on . Nivolumab significantly improved RFS for advanced melanoma compared with ipilimumab after 9 years of follow-up.

Accrual in this trial was suspended in March 2025 as a result of findings from the Checkmate 8HW trial, which showed that the ...

Findings seen in patients with microsatellite-instability-high or mismatch-repair-deficient metastatic colorectal cancer. (HealthDay News) — For patients with microsatellite-instability-high (MSI-H) ...

The US Food and Drug Administration (FDA) has approved nivolumab (Opdivo, Bristol Myers Squibb) with ipilimumab (Yervoy, Bristol Myers Squibb) for the treatment of adults and children aged 12 years ...